



Biosystems International raises € 2.1 Million to support development of lung cancer blood test

Paris, July 19, 2010 – Biosystems International (BSI) SAS, biotech leader in the development of monoclonal antibody based diagnostics for cancer, announced today that it has closed a round of funding amounting to €2.1 million (\$2.7 million).

Following the discovery of novel biomarkers for lung cancer, BSI launched the development of a new blood test for the detection of lung cancer in May, 2009. To complete development of the test and bring it to the market in 2011, BSI has raised €2.1 million, primarily from its principle investors.

The signing of the investment agreement continues a successful partnership among the contracting partners extending over several years. *“The renewed commitment by our shareholders demonstrates their confidence in our lung cancer program. These funds will help to accelerate our entry to market,”* said Jean-Pierre Tirouflet, Chief Executive Officer of Biosystems International.

Lung Cancer Diagnosis

The lung cancer specific antibodies discovered by BSI demonstrate a sensitivity and specificity superior to 80% following testing on several clinical cohorts totaling over 700 cancer patients and controls (for comparison, the PSA test for prostate cancer screening has a lower sensitivity and lower specificity).

These antibodies were discovered using the proprietary monoclonal antibody proteomics platform developed by BSI.

The new diagnostic test provides hope to millions of patients around the world as it can detect the disease at an early stage when surgical intervention is still possible, increasing dramatically the chances for survival. A simple non-invasive blood test for the early detection of lung cancer has the potential to dramatically increase the survival rate, saving many lives and significantly lowering the financial burden to society.

* * *

About Biosystems International

Biosystems International (BSI) is a biotechnology company specializing in the discovery and development of novel diagnostics for diseases with critical unmet needs. Using our proprietary monoclonal antibody proteomics process BSI rapidly discovers novel biomarkers and corresponding antibodies in a single step.

The company is currently focused on the discovery and development of diagnostic tests in the areas of cancer and chronic diseases as well as the development and commercialization of antibody arrays for plasma proteome profiling.

Contacts

- Jean-Pierre Tirouflet, President and CEO
- William Hempel, Director of Scientific Communications
- Tél : + 33 1 60 87 89 75
- info@biosys-intl.com

Safe Harbor Statement

Except for historical information contained herein, statements made in this release that would constitute forward-looking statements may involve certain risks and uncertainties. All forward-looking statements made in this release are based on currently available information and the company assumes no responsibility to update any such forward looking statements.